Literature DB >> 3663445

Characterisation of theophylline metabolism in human liver microsomes.

R A Robson1, A P Matthews, J O Miners, M E McManus, U A Meyer, P M Hall, D J Birkett.   

Abstract

1. A radiometric high performance liquid chromatographic method is described for the assay of theophylline metabolism in vitro by the microsomal fraction of human liver. 2. Formation of the three metabolites of theophylline (3-methylxanthine, 1-methylxanthine and 1,3-dimethyluric acid) were linear with protein concentrations to 4 mg ml-1 and with incubation times up to 180 min. 3. The coefficients of variation for the formation of 3-methylxanthine, 1-methylxanthine and 1,3-dimethyluric acid were 1.2%, 1% and 1.6%, respectively. 4. Theophylline is metabolised by microsomal enzymes with a requirement for NADPH. 5. The mean (n = 7) Km values for 1-demethylation, 3-demethylation and 8-hydroxylation were 545, 630 and 788 microM, respectively, and the mean Vmax values were 2.65, 2.84 and 11.23 pmol min-1 mg-1, respectively. 6. There was a high correlation between the Km and Vmax values for the two demethylation pathways suggesting that the demethylations are performed by the same enzyme. 7. Overall the in vitro studies are consistent with the in vivo results which suggest the involvement of two cytochrome P-450 isozymes in the metabolism of theophylline.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3663445      PMCID: PMC1386249          DOI: 10.1111/j.1365-2125.1987.tb03172.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  17 in total

1.  THE CARBON MONOXIDE-BINDING PIGMENT OF LIVER MICROSOMES. I. EVIDENCE FOR ITS HEMOPROTEIN NATURE.

Authors:  T OMURA; R SATO
Journal:  J Biol Chem       Date:  1964-07       Impact factor: 5.157

2.  Differential effects of cimetidine on theophylline metabolic pathways.

Authors:  J J Grygiel; J O Miners; R Drew; D J Birkett
Journal:  Eur J Clin Pharmacol       Date:  1984       Impact factor: 2.953

3.  Theophylline metabolism by the rat liver microsomal system.

Authors:  S M Lohmann; R P Miech
Journal:  J Pharmacol Exp Ther       Date:  1976-01       Impact factor: 4.030

4.  Effects of allopurinol on theophylline metabolism and clearance.

Authors:  J J Grygiel; L M Wing; J Farkas; D J Birkett
Journal:  Clin Pharmacol Ther       Date:  1979-11       Impact factor: 6.875

5.  Purification and characterization of six cytochrome P-450 isozymes from human liver microsomes.

Authors:  P P Wang; P Beaune; L S Kaminsky; G A Dannan; F F Kadlubar; D Larrey; F P Guengerich
Journal:  Biochemistry       Date:  1983-11-08       Impact factor: 3.162

6.  Theophylline-rifampicin interaction: non-selective induction of theophylline metabolic pathways.

Authors:  R A Robson; J O Miners; L M Wing; D J Birkett
Journal:  Br J Clin Pharmacol       Date:  1984-09       Impact factor: 4.335

7.  Nonlinear metabolic disposition of theophylline.

Authors:  R Dahlqvist; B Billing; J O Miners; D J Birkett
Journal:  Ther Drug Monit       Date:  1984       Impact factor: 3.681

8.  Secondary metabolism of theophylline biotransformation products in man--route of formation of 1-methyluric acid.

Authors:  D J Birkett; J O Miners; J Attwood
Journal:  Br J Clin Pharmacol       Date:  1983-01       Impact factor: 4.335

9.  Cigarette smoking and theophylline clearance and metabolism.

Authors:  J J Grygiel; D J Birkett
Journal:  Clin Pharmacol Ther       Date:  1981-10       Impact factor: 6.875

10.  Purification and characterization of liver microsomal cytochromes p-450: electrophoretic, spectral, catalytic, and immunochemical properties and inducibility of eight isozymes isolated from rats treated with phenobarbital or beta-naphthoflavone.

Authors:  F P Guengerich; G A Dannan; S T Wright; M V Martin; L S Kaminsky
Journal:  Biochemistry       Date:  1982-11-09       Impact factor: 3.162

View more
  26 in total

1.  Inter-individual variability in levels of human microsomal protein and hepatocellularity per gram of liver.

Authors:  Z E Wilson; A Rostami-Hodjegan; J L Burn; A Tooley; J Boyle; S W Ellis; G T Tucker
Journal:  Br J Clin Pharmacol       Date:  2003-10       Impact factor: 4.335

Review 2.  Pharmacokinetic interactions with felbamate. In vitro-in vivo correlation.

Authors:  P Glue; C R Banfield; J L Perhach; G G Mather; J K Racha; R H Levy
Journal:  Clin Pharmacokinet       Date:  1997-09       Impact factor: 6.447

3.  A study on the route of 1-methylurate formation in theophylline metabolism.

Authors:  C Bayar; I Ozer
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1997 Oct-Dec       Impact factor: 2.441

Review 4.  Pharmacokinetic drug interactions with oral contraceptives.

Authors:  D J Back; M L Orme
Journal:  Clin Pharmacokinet       Date:  1990-06       Impact factor: 6.447

5.  The glucuronidation of mycophenolic acid by human liver, kidney and jejunum microsomes.

Authors:  K Bowalgaha; J O Miners
Journal:  Br J Clin Pharmacol       Date:  2001-11       Impact factor: 4.335

Review 6.  Influence of endogenous and exogenous effectors on the pharmacokinetics of theophylline. Focus on biotransformation.

Authors:  U Tröger; F P Meyer
Journal:  Clin Pharmacokinet       Date:  1995-04       Impact factor: 6.447

7.  Metabolism of theophylline by cDNA-expressed human cytochromes P-450.

Authors:  H R Ha; J Chen; A U Freiburghaus; F Follath
Journal:  Br J Clin Pharmacol       Date:  1995-03       Impact factor: 4.335

8.  The effect of ciprofloxacin on theophylline pharmacokinetics in healthy subjects.

Authors:  K T Batty; T M Davis; K F Ilett; L J Dusci; S R Langton
Journal:  Br J Clin Pharmacol       Date:  1995-03       Impact factor: 4.335

9.  In vitro effect of fluoroquinolones on theophylline metabolism in human liver microsomes.

Authors:  M Sarkar; R E Polk; P S Guzelian; C Hunt; H T Karnes
Journal:  Antimicrob Agents Chemother       Date:  1990-04       Impact factor: 5.191

10.  In vitro-in vivo correlations for drugs eliminated by glucuronidation: investigations with the model substrate zidovudine.

Authors:  Sam Boase; John O Miners
Journal:  Br J Clin Pharmacol       Date:  2002-11       Impact factor: 4.335

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.